AUR-AG0J-TTM1-A-1-0-R-A743-41
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.540
- OXIDATIVE_PHOSPHORYLATION+0.520
- MYC_TARGETS_V1+0.460
- MYOGENESIS+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- E2F_TARGETS+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.270
- DNA_REPAIR+0.240
- ADIPOGENESIS+0.230
- PEROXISOME+0.220
Top 10 suppressed
- UV_RESPONSE_DN-0.420
- TGF_BETA_SIGNALING-0.410
- IL6_JAK_STAT3_SIGNALING-0.390
- TNFA_SIGNALING_VIA_NFKB-0.390
- INFLAMMATORY_RESPONSE-0.320
- PI3K_AKT_MTOR_SIGNALING-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- COMPLEMENT-0.290
- HEDGEHOG_SIGNALING-0.290
- MITOTIC_SPINDLE-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0I1-01A-11R-A21T-07 | — | E | 0.858 |
| 2 | SRR17866857 | — | — | 0.842 |
| 3 | TCGA-CQ-6225-01A-11R-1915-07 | — | — | 0.827 |
| 4 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.825 |
| 5 | TCGA-YC-A9TC-01A-22R-A39I-07 | — | — | 0.821 |
| 6 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.819 |
| 7 | SRR8942959 | — | — | 0.818 |
| 8 | TCGA-E2-A574-01A-11R-A29R-07 | — | E | 0.816 |
| 9 | fa77d98c-c26c-4a45-8c0d-3cb11173eb38 | — | — | 0.815 |
| 10 | TCGA-MZ-A6I9-01A-11R-A31N-07 | — | — | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.520 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| MYOGENESIS | 0.420 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |